Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting RAS-driven human cancer cells with antibodies to upregulated and essential cell-surface proteins
Alexander J. Martinko, Charles Truillet, Olivier Julien, et al.
eLife (2018) Vol. 7
Open Access | Times Cited: 89

Showing 1-25 of 89 citing articles:

Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xin Xie, Tingting Yu, Xiang Li, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 163
Modular cytokine receptor-targeting chimeras for targeted degradation of cell surface and extracellular proteins
Katarina Pance, Josef A. Gramespacher, James R. Byrnes, et al.
Nature Biotechnology (2022) Vol. 41, Iss. 2, pp. 273-281
Open Access | Times Cited: 130
Clinical trials, progression-speed differentiating features and swiftness rule of the innovative targets of first-in-class drugs
Yinghong Li, Xiao Xu Li, Jia Jun Hong, et al.
Briefings in Bioinformatics (2018) Vol. 21, Iss. 2, pp. 649-662
Open Access | Times Cited: 154
Structure-based development of new RAS-effector inhibitors from a combination of active and inactive RAS-binding compounds
Abimael Cruz-Migoni, Peter Canning, Camilo Quevedo, et al.
Proceedings of the National Academy of Sciences (2019) Vol. 116, Iss. 7, pp. 2545-2550
Open Access | Times Cited: 127
Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2
Colton J. Bracken, Shion A. Lim, Paige Solomon, et al.
Nature Chemical Biology (2020) Vol. 17, Iss. 1, pp. 113-121
Open Access | Times Cited: 100
Computer-aided drug repurposing for cancer therapy: Approaches and opportunities to challenge anticancer targets
Carla Mottini, Francesco Napolitano, Zhongxiao Li, et al.
Seminars in Cancer Biology (2019) Vol. 68, pp. 59-74
Open Access | Times Cited: 94
An Excitable Ras/PI3K/ERK Signaling Network Controls Migration and Oncogenic Transformation in Epithelial Cells
Huiwang Zhan, Sayak Bhattacharya, Huaqing Cai, et al.
Developmental Cell (2020) Vol. 54, Iss. 5, pp. 608-623.e5
Open Access | Times Cited: 76
Broad and thematic remodeling of the surfaceome and glycoproteome on isogenic cells transformed with driving proliferative oncogenes
Kevin K. Leung, Gary M. Wilson, Lisa L. Kirkemo, et al.
Proceedings of the National Academy of Sciences (2020) Vol. 117, Iss. 14, pp. 7764-7775
Open Access | Times Cited: 72
Maximizing CRISPRi efficacy and accessibility with dual-sgRNA libraries and optimal effectors
Joseph M. Replogle, Jessica L. Bonnar, Angela N. Pogson, et al.
eLife (2022) Vol. 11
Open Access | Times Cited: 66
The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance
Ian Ferguson, Bonell Patiño-Escobar, Sami T. Tuomivaara, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 64
High-throughput approaches for precision medicine in high-grade serous ovarian cancer
Meinusha Govindarajan, Christoph Wohlmuth, Matthew Waas, et al.
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 57
SurfaceGenie: a web-based application for prioritizing cell-type-specific marker candidates
Matthew Waas, Shana Terai Snarrenberg, Jack Littrell, et al.
Bioinformatics (2020) Vol. 36, Iss. 11, pp. 3447-3456
Open Access | Times Cited: 52
The CDCP1 Signaling Hub: A Target for Cancer Detection and Therapeutic Intervention
Tashbib Khan, Thomas Kryza, Nicholas Lyons, et al.
Cancer Research (2021) Vol. 81, Iss. 9, pp. 2259-2269
Open Access | Times Cited: 52
Surface Proteomics Reveals CD72 as a Target for In Vitro–Evolved Nanobody-Based CAR-T Cells in KMT2A/MLL1-Rearranged B-ALL
Matthew A. Nix, Kamal Mandal, Huimin Geng, et al.
Cancer Discovery (2021) Vol. 11, Iss. 8, pp. 2032-2049
Open Access | Times Cited: 52
Cell-surface tethered promiscuous biotinylators enable comparative small-scale surface proteomic analysis of human extracellular vesicles and cells
Lisa L. Kirkemo, Susanna K. Elledge, Jiuling Yang, et al.
eLife (2022) Vol. 11
Open Access | Times Cited: 36
Targeting a proteolytic neoepitope on CUB domain containing protein 1 (CDCP1) for RAS-driven cancers
Shion A. Lim, Jie Zhou, Alexander J. Martinko, et al.
Journal of Clinical Investigation (2022) Vol. 132, Iss. 4
Open Access | Times Cited: 32
Multiomics of azacitidine-treated AML cells reveals variable and convergent targets that remodel the cell-surface proteome
Kevin K. Leung, Aaron Nguyen, Tao Shi, et al.
Proceedings of the National Academy of Sciences (2018) Vol. 116, Iss. 2, pp. 695-700
Open Access | Times Cited: 52
Trimeric SARS-CoV-2 Spike interacts with dimeric ACE2 with limited intra-Spike avidity
Irene Lui, Xin Zhou, Shion A. Lim, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 49
Theranostic Targeting of CUB Domain Containing Protein 1 (CDCP1) in Pancreatic Cancer
Anna Moroz, Yung-Hua Wang, Jeremy Sharib, et al.
Clinical Cancer Research (2020) Vol. 26, Iss. 14, pp. 3608-3615
Open Access | Times Cited: 33
Activity-Based Diagnostics: Recent Advances in the Development of Probes for Use with Diverse Detection Modalities
Ryan K. Muir, Matteo Guerra, Matthew Bogyo
ACS Chemical Biology (2022) Vol. 17, Iss. 2, pp. 281-291
Closed Access | Times Cited: 21
A general approach for selection of epitope-directed binders to proteins
Jie Zhou, Chau Q. Le, Yun Zhang, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 19
Open Access | Times Cited: 4
CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease
Ning Zhao, Shalini Chopra, Kai Trepka, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 14, pp. 3066-3075
Open Access | Times Cited: 18
Engineered Proteins and Chemical Tools to Probe the Cell Surface Proteome
Kevin K. Leung, Kaitlin Schaefer, Zhi Lin, et al.
Chemical Reviews (2025)
Open Access
Effective targeting of intact and proteolysed CDCP1 for imaging and treatment of pancreatic ductal adenocarcinoma
Thomas Kryza, Tashbib Khan, Simon Puttick, et al.
Theranostics (2020) Vol. 10, Iss. 9, pp. 4116-4133
Open Access | Times Cited: 27
Switchable assembly and function of antibody complexes in vivo using a small molecule
Alexander J. Martinko, Erin F. Simonds, Suchitra Prasad, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 9
Open Access | Times Cited: 15
Page 1 - Next Page

Scroll to top